Derived from our findings high protein levels of PDGFRβ and VEGFR2 in primary untreated tumor specimens might help to identify ovarian cancer patients in whom platinum resistance and the potentially improved efficacy of PDGFR- and/or VEGFR-inhibition may balance toxicities and side effects of anti-angiogenic treatment. This evidence concerns the gene PDGFRB and ovarian cancer.